Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...

Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

March 3 (Reuters) - The U.S. Food and Drug Administration has warned Novo Nordisk over a consumer ad for its blockbuster ...

When it comes to making commercials, Western-wear manufacturer Tecovas is going cowboy.

Procter & Gamble, famous for launching ad characters like Mr. Clean and Mr. Whipple, is debuting Bruce, a dog who will help pitch Spruce to consumers ...

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...